www.prnewswire.com ·
Acs Guideline Reaffirms Abbott Leadership in Noninvasive Colorectal Cancer Screening
Topic context
This topic has been covered 246115 times in the last 7 days across our monitored publishers.
The full article is on the original publisher site.
AI insight
AI-generatedAbbott's noninvasive CRC screening portfolio gains guideline reaffirmation, potentially expanding market share in the US colorectal cancer screening market. The introduction of a blood-based test could further strengthen Abbott's position. Impact is company-specific (Abbott) and US-focused, with no direct commodity or supply chain scarcity. Commercial mechanism is weak: guideline reaffirmation may support revenue growth but no immediate pricing or supply shock.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- ACS updated CRC screening guidelines reaffirm Abbott's Cologuard and Cologuard Plus as preferred noninvasive options for adults 45+ at average risk.
- Cologuard Plus has 95% detection rate for colorectal cancers at 94% specificity.
- Abbott plans to introduce a blood-based CRC test from Freenome pending FDA approval.
Related stories
latimes.com
Mayor Karen Bass Is in Toughest Reelection Fight of Her Career She Says She Intends to Win It
cnn.com
Economy Inflation Affordability Breaking Point
prnewswire.com
Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer
businessday.co.za
2026 05 27 ndabeni bets on small business to deliver on south africas democratic promise
hellenicshippingnews.com